Comparative Pharmacology
Head-to-head clinical analysis: VENCLEXTA versus VENETOCLAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VENCLEXTA versus VENETOCLAX.
VENCLEXTA vs VENETOCLAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of B-cell lymphoma-2 (BCL-2) protein, restoring apoptosis in malignant cells.
Venetoclax is a selective B-cell lymphoma-2 (BCL-2) inhibitor. It binds directly to the BCL-2 protein, displacing pro-apoptotic proteins such as BIM, leading to mitochondrial outer membrane permeabilization and activation of caspases, resulting in apoptosis. BCL-2 is overexpressed in various hematologic malignancies, particularly chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
VENCLEXTA (venetoclax) is administered orally. For chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): dose escalation schedule (Week 1: 20 mg daily; Week 2: 50 mg daily; Week 3: 100 mg daily; Week 4: 200 mg daily; Week 5+: 400 mg daily) in combination with obinutuzumab or rituximab. For acute myeloid leukemia (AML): 600 mg orally daily on Days 1-28 in combination with azacitidine or decitabine, or low-dose cytarabine, in 28-day cycles.
Oral, 400 mg once daily after a 5-week ramp-up schedule (20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, 200 mg daily for week 4, then 400 mg daily thereafter). For CLL/SLL, continue until disease progression or unacceptable toxicity. For AML, dosing is 600 mg daily on days 2-21 in combination with azacitidine or decitabine, or 400 mg daily on days 2-21 with low-dose cytarabine.
Clinical Note
moderateVenetoclax + Digoxin
"Venetoclax may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateVenetoclax + Digitoxin
"Venetoclax may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateVenetoclax + Deslanoside
"Venetoclax may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateVenetoclax + Acetyldigitoxin
"Venetoclax may decrease the cardiotoxic activities of Acetyldigitoxin."
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours. Supports once-daily dosing with steady-state achieved within 3–5 days.
Terminal elimination half-life ranges from 14 to 27 hours (mean ~16 hours) in patients with hematologic malignancies. At steady state, accumulation is minimal; once-daily dosing maintains therapeutic concentrations.
Primarily fecal (approximately 90% of absorbed dose), with <1% excreted renally as unchanged drug. Biliary excretion contributes to fecal elimination.
Primarily fecal (approximately 99.9%), with less than 1% excreted renally as unchanged drug. Biliary/fecal elimination is the major route, with negligible renal clearance.
Category C
Category C
BCL-2 Inhibitor
BCL-2 Inhibitor